Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Key Highlights
- ➤Xenon paused new enrollment in MDD and bipolar depression studies after neuropsychiatric adverse-event analysis
- ➤Xenon shares fell $17.60, or 30.7%, to $39.75 on September 18, 2026
- ➤Phase 3 X-NOVA2 trial evaluates 20-mg azetukalner in approximately 450 MDD patients
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD.
Get started
Create a free account to read the full story.